MEDICAL DISCLAIMERThis page is for educational purposes only and is not medical advice. A lab report does not guarantee safety. If you experience symptoms after consuming mad honey, contact Poison Control (1-800-222-1222 in the US) or emergency services immediately. |
KEY TAKEAWAYS
|
What Is a Certificate of Analysis?
A Certificate of Analysis (COA) is a document issued by an analytical laboratory confirming the results of testing a specific sample or batch. For mad honey, a legitimate COA should link to a specific batch — with traceability from the tested sample to the product you are purchasing.
COAs are only as reliable as the laboratory that issued them. Key indicators of a credible COA:
- Issued by an accredited third-party laboratory, not an in-house vendor test
- Includes the laboratory’s accreditation number (e.g., ISO/IEC 17025 accreditation)
- Specifies the analytical method and instrumentation used
- Reports individual GTX variant concentrations, not just a total
- Includes limits of detection (LOD) and limits of quantification (LOQ)
- Provides a unique sample ID or batch number traceable to the product
Key Fields in a Mad Honey COA
Grayanotoxin I (GTX I) Concentration
Unit: mg/kg (milligrams per kilogram of honey), equivalent to μg/g
What it means: GTX I is the most potent and most pharmacologically studied variant. It is the primary driver of cardiovascular effects documented in clinical case literature. EFSA’s 2023 risk assessment uses GTX I as one of the two primary exposure metrics.
What a valid result looks like: A specific numerical value such as ‘GTX I: 12.4 mg/kg’, or ‘Not Detected (< 0.6 mg/kg)’ with the LOQ value specified.
Red flags: No separate GTX I value (only a ‘total GTX’ figure); no LOQ or LOD provided alongside an ND result.
Grayanotoxin III (GTX III) Concentration
Unit: mg/kg
What it means: GTX III is the most frequently detected variant in commercial mad honey samples and is included alongside GTX I in EFSA’s primary exposure metric (GTX I + III sum). Published commercial samples show GTX III as the dominant variant by concentration, with reported values up to 68.754 mg/kg.
Grayanotoxin II (GTX II) Concentration
What it means: Less potent than GTX I; included in comprehensive analyses but not always reported separately. A COA that includes GTX II reporting indicates more thorough testing.
Analytical Method
Common values: HPLC-UV, LC-MS/MS, HPLC-DAD
HPLC-UV: Standard method; LOD approximately 0.2 mg/kg for GTX I, 0.1 mg/kg for GTX III. Adequate for products above 1 mg/kg. Results near the LOQ carry higher measurement uncertainty.
LC-MS/MS: Higher sensitivity and specificity than HPLC-UV. EFSA’s 2023 assessment recommended LOQ targets of ≤ 0.01 mg/kg for regulatory monitoring. Preferable for low-concentration products where HPLC-UV may not reliably distinguish low GTX from analytical noise.
If the COA does not specify the method, the result cannot be interpreted with confidence.
Limit of Detection (LOD)
Definition: The lowest concentration the method can detect as present, but not reliably quantify. Below LOD = ‘Not Detected.’
Context: Published HPLC method LODs are approximately: GTX I: 0.2 mg/kg; GTX III: 0.1 mg/kg. If a COA reports ‘Not Detected’ for GTX I with an LOD of 2 mg/kg, the test would not have detected GTX I at concentrations up to 1.9 mg/kg. A higher LOD means less confident interpretation of an ND result.
Limit of Quantification (LOQ)
Definition: The lowest concentration the method can reliably quantify numerically.
Context: Published LOQs are approximately: GTX I: 0.6 mg/kg; GTX III: 0.3 mg/kg. Results between LOD and LOQ can confirm presence, but not precise concentration. Results above LOQ are quantitatively reliable within the method’s stated precision.
Sample / Batch Identification
What to look for: A unique batch number, harvest date, or sample ID that you can cross-reference with the product packaging or vendor description.
Why it matters: Batch-to-batch GTX concentration variation in mad honey is documented in published research. A COA from a different batch than the product you receive provides no reliable information about that product’s actual GTX content.
Red flag: A COA with no batch identifier, or one described as a ‘representative sample’ or ‘product type average.’
Laboratory Accreditation
What to look for: ISO/IEC 17025 accreditation — the international standard for testing and calibration laboratory competence, covering measurement uncertainty management, equipment calibration, and result traceability.
An accreditation number should be verifiable on the accreditation body’s public registry — for example, UKAS in the UK, A2LA in the US, or DAkkS in Germany.
Calculating Your Dose From a COA
Once you have the GTX I and GTX III values from a COA, you can calculate the expected dose for a given serving:
| Dose Calculation Dose (mg) = [GTX I (mg/kg) + GTX III (mg/kg)] ÷ 1000 × Serving weight (g) Example: GTX I = 8 mg/kg, GTX III = 22 mg/kg, serving = 15g Dose = (8 + 22) ÷ 1000 × 15 = 0.45 mg total GTX I + III Dose per kg body weight (μg/kg) = (Dose in mg × 1000) ÷ Body weight (kg) For a 70 kg adult: 0.45 × 1000 ÷ 70 = 6.4 μg/kgEFSA’s reference point (BMDL10): 15.3 μg/kg body weight |
Note: These calculations use only GTX I and GTX III. Other variants not captured by the COA may contribute additional biological activity.
What a COA Cannot Tell You
Even a complete, accredited COA cannot answer the following questions:
- Whether the product you received matches the tested batch. Unless you received the product directly from the tested batch, concentration variation between batches is a documented limitation.
- What GTX variants beyond I, II, and III are present? Standard HPLC methods do not capture the full grayanotoxin profile. More than 20 variants have been identified in Rhododendron species.
- How your body will respond to the reported dose. Individual variation in GTX absorption, metabolism, and cardiovascular sensitivity is substantial and cannot be predicted from the concentration figure alone.
- Whether the product is safe for you specifically. A COA is a measurement document, not a safety clearance. Your health status, medications, and individual risk factors are not assessed by the lab.
Sources
- Silici S, et al. (2014). Grayanotoxin-III detection and antioxidant activity of mad honey. International Journal of Food Properties. https://doi.org/10.1080/10942912.2014.999866
- EFSA CONTAM Panel (2023). Risks for human health related to the presence of grayanotoxins in certain honey. EFSA Journal, 21(3), e7866. https://doi.org/10.2903/j.efsa.2023.7866
- Jansen SA, et al. (2012). Grayanotoxin poisoning: ‘mad honey disease’ and beyond. Cardiovascular Toxicology, 12(3), 208–215. https://pmc.ncbi.nlm.nih.gov/articles/PMC3404272/
- Aryal N, et al. (2025). Grayanotoxins in mad honey: mechanisms of toxicity, clinical management, and therapeutic implications. Journal of Applied Toxicology. https://doi.org/10.1002/jat.4855
NEXT READS
